Evotec and Variant Bio partner to develop fibrosis treatments
Drug Discovery World
APRIL 24, 2024
Evotec and Variant Bio have announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Despite the chronic nature of fibrotic conditions, widespread impact on various organs, and substantial disease burden, there is currently no curative treatment for these conditions. The strategic partnership will combine Variant Bio’s genomic discovery capabilities and VB-Inference platform with Evotec’s knowledge of antifibrotic drug discovery.
Let's personalize your content